Oncology & Cancer

FDA approves pembrolizumab plus axitinib for advanced RCC

(HealthDay)—The combination of pembrolizumab and axitinib has been approved as a first-line treatment in advanced renal cell carcinoma (RCC), the U.S. Food and Drug Administration announced Friday.

HIV & AIDS

New drug adds to arsenal against AIDS

A new drug, rilpivirine, can add powerfully to the combination of medications used to control HIV for first-time patients, researchers conclude in Friday's issue of The Lancet.

Oncology & Cancer

New combination drug controls tumor growth and metastasis in mice

Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide ...

page 6 from 33